6533b7d0fe1ef96bd125ad5f

RESEARCH PRODUCT

Cetuximab: clinical results in colorectal cancer

Francesco GiulianiR. AgueliGiuseppe ColucciVittorio GebbiaA. PianoEvaristo Maiello

subject

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineHumansEpidermal growth factor receptorNeoplasm MetastasisRandomized Controlled Trials as TopicChemotherapyCetuximabbiologybusiness.industryAntibodies MonoclonalHematologymedicine.diseaseChemotherapy regimendigestive system diseasesSurgeryRadiation therapyClinical trialClinical PracticeClinical Trials Phase III as TopicOncologybiology.proteinColorectal Neoplasmsbusinessmedicine.drug

description

In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.

yearjournalcountryeditionlanguage
2007-06-01Annals of Oncology
https://doi.org/10.1093/annonc/mdm216